SEAGULL HEALTH
Your health,We care!
Its core advantages lie in comprehensive and potent efficacy, outstanding intracranial activity, broad anti-resistance coverage, superior safety profile, and high accessibility.
AuthenticGuaranteeFast DeliveryPrivacy On March 3, 2021, Furmonertinib was approved for the treatment of adult
patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
who have experienced disease progression during or after prior treatment with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and
been confirmed as EGFR T790M mutation-positive by testing.
On June 29, 2022, Furmonertinib was approved for the first-line treatment of
adult patients with locally advanced or metastatic non-small cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions or
exon 21 (L858R) substitution mutations.
On June 29, 2022, Shanghai Acebright Pharmaceutical Technology Co., Ltd. (Stock Code: 688578) announced that Furmonertinib Mesylate (trade name: Afure···【Read More】
Update: 02 Feb,2026Source: Haiou HealthViews: 113
On March 3, 2021, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Furmonertinib Mesylate Tablets···【Read More】
Update: 02 Feb,2026Source: Haiou HealthViews: 121
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
